NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

The National Institute for Health and Care Excellence (NICE) has maintained its decision not to recommend two treatments for Alzheimer’s disease on the NHS, after concluding that they still do not ...

Kisunla (donanemab-azbt) is a prescription drug that’s used to treat Alzheimer’s disease in adults. This drug currently isn’t known to interact with other drugs. Note: As a person’s ...

Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage ...

They do not treat the cause of Alzheimer’s disease. Kisunla offers a new approach to treat early Alzheimer’s disease. It targets the root cause of Alzheimer’s to help slow how quickly ...

Australia's competition watchdog said on Wednesday that Singapore Telecommunications-owned Optus has reached a settlement ...

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks. Kamala ...

The Food and Drug Administration approved the drug, now marketed as Kisunla, in July of 2024. It's one of two drugs approved since 2023 that can clear the brain of sticky amyloid plaques ...